Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Aziende Chimiche Riunite Angelini Francesco – A.C.R.A.F. S.p.A., Viale Amelia 70, 00181, Rome Italy
Latuda 18.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). White to off-white, film-coated round tablets of 6 mm debossed with ‘LA’. |
Each film-coated tablet contains lurasidone hydrochloride equivalent to18.6 mg lurasidone.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lurasidone |
Lurasidone is a selective blocking agent of dopamine and monoamine effects indicated for the treatment of schizophrenia. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7 receptors. Lurasidone does not bind to histaminergic or muscarinic receptors. |
| List of Excipients |
|---|
|
Core: Mannitol (E421) Tablet coating: Hypromellose 2910 (E464) |
Cartons contain 14 × 1, 28 × 1, 30 × 1, 56 × 1, 60 × 1, 90 × 1 or 98 × 1 tablets in aluminium/aluminium perforated unit dose blisters.
Not all pack sizes may be marketed.
Aziende Chimiche Riunite Angelini Francesco – A.C.R.A.F. S.p.A., Viale Amelia 70, 00181, Rome – Italy
EU/1/14/913/001-007
Date of first authorisation: 21 March 2014
Date of latest renewal: 14 November 2018
| Drug | Countries | |
|---|---|---|
| LATUDA | Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
